// App-Quantinova.ai

392 : Azathioprine immunosuppression and disease modification in Parkinson’s disease (AZA-PD): a randomised double-blind placebo-controlled phase II clinical trial

Researchers

Presenter

  • J. Greenland

Principal Investigators

  • E. Cutting

  • S. Kadyan

  • S. Bond

  • A. Chhabra

  • C. Williams-Gray

Medical Centers

  • N/A

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Parkinson's disease

Biomarkers

  • Cerebrospinal fluid

  • MDS-Unified Parkinson's Disease Rating Scale

Drug/Treatment

  • Oraprine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • ISRCTN14616801

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved